

## **Osteoporose: Prävention, Diagnostik und Therapie Empfehlungen 2015 Schweizerische Vereinigung gegen Osteoporose (SVGO)**

### *Literatur*

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2013; 24(1):23-57.

Dachverband Osteologie. DVO-Leitlinie 2014 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. <http://www.dv-osteologie.org> 2014.

National Osteoporosis Foundation (NOF). Clinician's Guide to Prevention and Treatment of Osteoporosis 2008 and Update 2014. [www.nof.org](http://www.nof.org)

National Osteoporosis Guideline Group (NOGG). Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Update 2014. [www.shef.ac.uk/NOGG/](http://www.shef.ac.uk/NOGG/)

Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. *Joint Bone Spine* 2012; 79(3):304-313.

McCloskey E, Kanis JA, Johansson H, Harvey N, Oden A, Cooper A et al. FRAX-based assessment and intervention thresholds-an exploration of thresholds in women aged 50 years and older in the UK. *Osteoporos Int* 2015:epub.

Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. *Osteoporos Int* 2010; 21:381-389.

Lippuner K, Grifone S, Schwenkglens M, Schwab P, Popp AW, Senn C et al. Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. *Osteoporos Int* 2012; 23(3):829-839.

Lippuner K, Popp AW, Schwab P, Gitlin M, Schaufler T, Senn C et al. Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. *Osteoporos Int* 2011; 22(9):2487-2497.

Lippuner K, Johansson H, Kanis JA, Rizzoli R. FRAX assessment of osteoporotic fracture probability in Switzerland. *Osteoporos Int* 2010; 21(3):381-389.

Svedbom A, Ivergard M, Hernlund E, Rizzoli R, Kanis JA. Epidemiology and economic burden of osteoporosis in Switzerland. *Arch Osteoporos* 2014; 9:187.

Rizzoli R, Boonen S, Brandi ML, Bruyere O, Cooper C, Kanis JA et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Curr Med Res Opin* 2013; 29(4):305-313.

Bischoff-Ferrari H, Keller U, Burckhardt P, Quack Lötscher K, Gerber B, l'Allemand D et al. Empfehlung der Eidgenössischen Ernährungscommission zur Vitamin D Zufuhr für die Schweizer Bevölkerung. *Swiss Medical Forum* 2012; 12:775-778.

Watts NB, Ettinger B, Leboff MS. FRAX facts. *J Bone Miner Res* 2009; 24(6):975-979.

Leslie WD, Lix LM. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. *J Bone Miner Res* 2011; 26(3):460-467.

Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. A comparative study of using non-hip bone density inputs with FRAX(R). *Osteoporos Int* 2012; 23(3):853-860.

Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. *Osteoporos Int* 2011; 22(3):809-816.

McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A, Bonnet N et al. Vertebral Fracture Assessment (VFA) with a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis. *J Bone Miner Res* 2008;(1523-4681 (Electronic)).

Rosen HN, Vokes TJ, Malabanan AO, Deal CL, Alele JD, Olinginski TP et al. The Official Positions of the International Society for Clinical Densitometry: vertebral fracture assessment. *J Clin Densitom* 2013; 16(4):482-488.

Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. *J Bone Miner Res* 2014; 29(3):518-530.

Harvey NC, Gluer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. *Bone* 2015; 78:216-224.

Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnerio P, Griesmacher A et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. *Osteoporos Int* 2011; 22(2):391-420.

Meier C, Lamy O, Krieg MA, Mellinshof HU, Felder M, Ferrari S et al. The role of teriparatide in sequential and combination therapy of osteoporosis. *Swiss Med Wkly* 2014; 144:w13952.

Rizzoli R, Branco J, Brandi ML, Boonen S, Bruyere O, Cacoub P et al. Management of osteoporosis of the oldest old. *Osteoporos Int* 2014; 25(11):2507-2529.

Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? *N Engl J Med* 2012; 366(22):2051-2053.

Roux C, Briot K. How long should we treat? *Osteoporos Int* 2014; 25(6):1659-1666.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. *Am J Med* 2013; 126(1):13-20.

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. *Osteoporos Int* 2012.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2014; 29(1):1-23.

Allen MR, Ruggiero SL. A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field. *Int J Oral Maxillofac Implants* 2014; 29(1):e45-e57.